(Q46965886)

26 December 2017

title

Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30%. (English)

1 reference

26 December 2017

1 reference

2

Mihai Gheorghiade

1 reference

26 December 2017

3

Faiez Zannad

1 reference

26 December 2017

1

Bertram Pitt

1 reference

PubMed ID

16504579

26 December 2017

Dirk J van Veldhuisen

5

object named as

Dirk J van Veldhuisen

1 reference

26 December 2017

Ramon Corbalan

7

object named as

Ramon Corbalan

1 reference

26 December 2017

EPHESUS Investigators

11

object named as

EPHESUS Investigators

1 reference

26 December 2017

author name string

Jeffrey L Anderson

4

1 reference

26 December 2017

Alexander Parkhomenko

6

1 reference

26 December 2017

Eric Q Klug

8

1 reference

26 December 2017

Robin Mukherjee

9

1 reference

26 December 2017

Henry Solomon

10

1 reference

26 December 2017

publication date

28 February 2006

1 reference

26 December 2017

European Journal of Heart Failure

published in

1 reference

26 December 2017

volume

8

1 reference

26 December 2017

page(s)

295-301

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Spironolactone improves angiotensin-induced vascular changes and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Endothelial cell swelling by aldosterone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.11.008

10.1016/J.EJHEART.2005.11.008

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

release_wmpukl2ry5c6voj4m5wyg4v75y

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wmpukl2ry5c6voj4m5wyg4v75y

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

16504579

1 reference

26 December 2017